IAP7 Rec'd PCT/PTO 13 JAN 2006

TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER FISHMAN18A

U.S. APPLICATION NO. (If known see 37 GER 1.5)

INTERNATIONAL APPLICATION NO. PCT/IL2005/001166

INTERNATIONAL FILING DATE

PRIORITY CLAIMED

November 8, 2005

November 8, 2004

TITLE OF INVENTION

THERAPEUTIC TREATMENT OF ACCELERATED BONE RESORPTION

APPLICANT(S) FOR DO/EO/US

Pnina FISHMAN et al.								
Applica	ant	herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:						
1. [2	_	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
2. [i	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3.	-	This is an express request to begin national examination procedures (35 U.S.C. 371(f)) as soon as the application is in order for						
•	•	such purpose and the applicable requirements of 35 U.S.C. 371(c) have been complied with.						
4. [1	The US has been elected (Art 31).						
-	-	A copy of the International Application as filed (35 U.S.C. 371(c)(2))						
-	-	a. [] is attached hereto (required only if not transmitted by the International Bureau).						
	•	b. [X] has been communicated by the International Bureau.						
		c. [] is not required, as the application was filed in the United States Receiving Office (RO/US).						
6. []	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
ι -		a. [] is attached hereto.						
		b. [] has been previously submitted under 35 U.S.C. 154(d)(4).						
. Ţ. [2	(]	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))						
•		a. [] are transmitted herewith (required only if not transmitted by the International Bureau).						
		b. [] have been communicated by the International Bureau.						
		c. [] have not been made; however, the time limit for making such amendments has NOT expired.						
		d. [X] have not been made and will not be made.						
8. []	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).						
9. [2	(]	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).						
10. [-	An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).						
		to 16. below concern document(s) or information included:						
_	_	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
_	_	An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
-	-	A FIRST preliminary amendment.						
		An Application Data Sheet under 37 CFR 1.76.						
		A substitute specification.						
		A change of power of attorney and/or address letter.						
		A computer-readable sequence form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.						
		A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)						
		Other items or information:						
L		[X] Courtesy copy of the International Application as filed.						
		[X] Formal drawings, 12 sheets, Figures 1A-10D.						

[X] The application is (or will be) assigned to: CAN-FITE BIOPHARMA LTD. whose address is 10 Bareket Street, Petach Tikva

Page 1 of 2

49170, Israel.

IAP20 Rec'd FCT/PTO 13 JAN 2006

U.S. APPHICATION NO 71f Known, see 37 EFR 1.5) International Application No. PCT/IL2005/001166							Attorney's Docket No. FISHMAN18A				
21. The following fees are submitted:						CALCULATIONS PTO USE ONLY					
21. The following fees an	c saomme	CAL	CALCULATIONS FIGURE ONLY								
[xx] a) BASIC NATI	ONAL FI										
[xx] b) SEARCH FE	E (37 CFI	i									
[] US was Inter	national S										
[xx] Other ISR p	rovided to										
[] All other situ	ations	\$900	0.00								
[xx] c) EXAMINATI	ON FEE										
[] IPEA/US ga	ve wholly										
[xx] All other sit	uations	ł									
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 \$ months from the earliest claimed priority date (37 CFR 1.492(h)).											
TOTAL SHEETS EXTRA	SHEETS		of each additional 50 or fra	ction	RATE						
45 100	thereof (ro		ound up to a whole numbe	r)							
45 - 100 CLAIMS	/50	er Filed	Number Extra	Rate (X \$250.00						
Total Claims	10 - 20 =		Ivalitoer Extra	Rate (1.492 (d-f)) X \$ 50.00		\$					
Independent Claims	1 - 3 =			X \$200.		\$		 			
Multiple Dependent Claims (if applicable)		<u> </u>	+ \$36	+ \$360.00						
		\$900.									
Reduction of ½ for filing by small entity, if applicable. Applicant claims small entity status. See 37 \$450.00 CFR 1.27.											
SUBTOTAL = \$450.00											
Processing fee of \$130.00 for		\$									
months from the earliest clair	ned priority	\$450.	00								
Fee for recording the enclose	d assignmen	\$		 							
accompanied by an appropria	ite cover she	\$450.0	00								
			Amount to be:	\$							
		L	refunded	3							
							charged	\$			
Payment Method (check one only)											
a. [] A check in the am	ount of \$		to cover the above	fees is e	nclosed.						
b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$ 450.00, is attached.											
c. [] Please charge my Deposit Account No. 02-4035 in the amount of \$ to cover the above fees.											
c. [] Please charge my Deposit Account No. 02-4035 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.											
Handling of Fee Deficiencies (check one only)											
[X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4035. A duplicate copy of this sheet is enclosed.											
[] If a deficiency exists in the basic national fee set by 37 CFR 1.492(a), please charge it to Deposit Account 02-4035. At this time,											
no authorization is given to charge any other fees.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Direct all correspondence to the address associated with CUSTOMER NUMBER 001444, which is currently:											
BROWDY AND NE	URE r L. Browdy										
624 NINTH STREET, N.W., SUITE 300 NAME											
WASHINGTON, D.	C. 20001	l	-			25,618					
TEL: (202) 628-5197 FAX: (202) 737-3528					i	REGIST	RATION NUMBE	R			
Date of this submission: January 13, 2006 RLB:lmh											
BROWDY AND NEIMARK Form BN-1390 (REVISED 2/03/05) RLB:IIIII Page 2 of 2											